Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
20.85
-0.18 (-0.86%)
At close: Feb 6, 2026, 4:00 PM EST
21.39
+0.54 (2.59%)
After-hours: Feb 6, 2026, 6:41 PM EST
Nanobiotix Revenue
Nanobiotix had revenue of 13.32M EUR in the half year ending June 30, 2025, with 186.77% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M.
Revenue (ttm)
10.16M EUR
Revenue Growth
-75.93%
P/S Ratio
85.95
Revenue / Employee
98,621 EUR
Employees
103
Market Cap
1.03B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.10% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -243.00K | -6.53% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.35% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 1.18M | 73.67% |
| Dec 31, 2013 | 1.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Iovance Biotherapeutics | 250.43M |
| Phathom Pharmaceuticals | 147.19M |
| ARS Pharmaceuticals | 142.77M |
| Theravance Biopharma | 80.33M |
| EyePoint | 42.34M |
| Vir Biotechnology | 16.86M |
| Aktis Oncology | 5.56M |
NBTX News
- 25 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 7 weeks ago - NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris - GlobeNewsWire
- 2 months ago - Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Participate in Investor Conferences the Week of November 10th - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth - GlobeNewsWire
- 4 months ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 4 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire